Gilder Gagnon Howe Co Lowers stake in BioMarin Pharmaceutical (BMRN)

BioMarin Pharmaceutical (BMRN) : Gilder Gagnon Howe Co reduced its stake in BioMarin Pharmaceutical by 2.01% during the most recent quarter end. The investment management company now holds a total of 461,689 shares of BioMarin Pharmaceutical which is valued at $46,842,966 after selling 9,487 shares in BioMarin Pharmaceutical , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.BioMarin Pharmaceutical makes up approximately 0.87% of Gilder Gagnon Howe Co’s portfolio.

Other Hedge Funds, Including , California State Teachers Retirement System boosted its stake in BMRN in the latest quarter, The investment management firm added 2,882 additional shares and now holds a total of 343,527 shares of BioMarin Pharmaceutical which is valued at $34,854,249. BioMarin Pharmaceutical makes up approx 0.07% of California State Teachers Retirement System’s portfolio.Pitcairn Co boosted its stake in BMRN in the latest quarter, The investment management firm added 734 additional shares and now holds a total of 7,791 shares of BioMarin Pharmaceutical which is valued at $764,219. BioMarin Pharmaceutical makes up approx 0.10% of Pitcairn Co’s portfolio.Hartford Investment Management Co boosted its stake in BMRN in the latest quarter, The investment management firm added 70 additional shares and now holds a total of 2,906 shares of BioMarin Pharmaceutical which is valued at $271,943. BioMarin Pharmaceutical makes up approx 0.01% of Hartford Investment Management Co’s portfolio.

BioMarin Pharmaceutical closed down -1.84 points or -1.81% at $99.62 with 14,58,037 shares getting traded on Thursday. Post opening the session at $102.41, the shares hit an intraday low of $99.14 and an intraday high of $102.49 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, BioMarin Pharmaceutical reported $-2.61 EPS for the quarter, missing the analyst consensus estimate by $ -2.52 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.09. The company had revenue of $300.10 million for the quarter, compared to analysts expectations of $279.05 million. The company’s revenue was up 20.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.51 EPS.

BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Company’s product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha) Naglazyme (galsulfase) Kuvan (sapropterin dihydrochloride) Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States the European Union. Aldurazyme which was developed in collaboration with Genzyme Corporation (Genzyme) was approved for marketing in the United States the European Union and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).

Leave a Reply

BioMarin Pharmaceutical - Is it time to Sell?

Top Brokerage Firms are advising their investors on BioMarin Pharmaceutical. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.